Pharmaceutical

Menarini signs agreement for Astellas’s rheumatoid arthritis therapy

Menarini Asia-Pacific has entered a long-term exclusive agreement to license Astellas Pharma’s Smyraf to treat rheumatoid arthritis.

Sep 13, 2023 - 20:00
Menarini signs agreement for Astellas’s rheumatoid arthritis therapy
Menarini Asia-Pacific has entered a long-term exclusive agreement to license Astellas Pharma’s Smyraf to treat rheumatoid arthritis.
Read the original article

Tags:

Previous Article

Signal: Roche to refile subcutaneous Tecentriq with FDA after UK approval

Next Article

Dewpoint and Chemify partner for cancer drug discovery

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Dermavant maps out atopic dermatitis filing after positive Phase III data 

Dermavant maps out atopic dermatitis filing after posit...

Jan 13, 2024

OMERS snaps up drug royalties and milestones from Xencor for $215m

OMERS snaps up drug royalties and milestones from Xenco...

Nov 8, 2023

Eli Lilly reiterates POINT acquisition plans with tender offer extension

Eli Lilly reiterates POINT acquisition plans with tende...

Nov 12, 2023